Tagrisso fda approval date?

Tagrisso (osimertinib) was first approved by the FDA on November 13, 2015, for metastatic EGFR T790M mutation–positive NSCLC after progression on EGFR-TKI therapy (accelerated approval). If you need the approval date for a specific indication (e.g., first-line use, adjuvant setting), tell me which one and I’ll pull that date.